Short answer: they are used for different things and both have thin human evidence. GHK-Cu is a natural copper peptide whose best-known use is topical skin care; its human trials are a handful of small gel and cream studies. BPC-157 is a synthetic peptide sold for tendon, joint and gut healing; its human data are five small reports. Both are injected by some users, but neither has been tested as an injection for skin, hair or sports recovery in a controlled trial, and the FDA warns that injected forms of both can trigger immune reactions.
GHK-Cu vs BPC-157 at a glance
| GHK-Cu | BPC-157 | |
|---|---|---|
| What it is | Copper-binding tripeptide (copper peptide) | Synthetic gastric pentadecapeptide (15-amino-acid peptide) |
| Approval | Not approved; furthest stage: Small randomized trials of skin products; injections untested in humans | Not approved; furthest stage: Phase 2 (one ulcerative colitis trial, reported only as a 2005 meeting abstract) |
| Human studies (counted in our records) | 3 | 5 |
| Half-life | Not established in humans | Not established in humans |
| Testosterone suppression score | Not established | Not established |
| Liver risk score | Not established | Not established |
| Evidence score | 1/3 | 0/3 |
| WADA | Not named on the 2026 List (S0 may apply) | Prohibited at all times (S0 Non-approved substances) |
| Main use | Skin care (topical), hair, wound healing | Tendon, joint and gut healing |
| Natural? | Yes, found in blood (levels fall with age) | No, synthetic (based on a gastric protein) |
| SwissChems product | GHK-Cu Copper Peptide | BPC-157 (0.5mg/capsule), 60 Capsules |
Scores run from 0 (none) to 3 (high); see our methodology. Data from the SARMs database.
Source: Sarmguide compound database; GHK-Cu: A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials (2026).
What each is
GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a three-amino-acid peptide that binds copper. It occurs naturally in blood, with average levels falling from about 200 ng/mL at age 20 to 80 ng/mL by age 60, and it is a common cosmetic ingredient (copper tripeptide-1). BPC-157 is a synthetic 15-amino-acid peptide derived from a protein in gastric juice; its molecular target is unknown.
What the human evidence shows
| Use | GHK-Cu | BPC-157 |
|---|---|---|
| Wounds and ulcers | Gel improved diabetic foot ulcer closure (98.5% vs 60.8%); cream did not help venous leg ulcers | No wound trial in people |
| Skin | Mixed results after laser resurfacing (13 patients); small facial-cream studies | Not studied |
| Hair | Lotion with GHK plus 5-ALA raised hair counts in 45 men (combined product) | Not studied |
| Joints and tendons | Not studied in people | 16-person knee-pain chart review, no control group |
| Gut | Not studied | 53-person ulcerative colitis trial (abstract only); benefit not shown |
| Injections | Never tested in humans | Small IV and local-injection reports only |
Side effects and safety
Topical GHK-Cu products reported few side effects in small trials. For injectable GHK-Cu, the FDA cites possible immune reactions from aggregation and impurities and limited human data. For BPC-157, the enema studies reported headache and flatulence at placebo-like rates, and the FDA holds three adverse event reports (injection-site swelling, shortness of breath, skin darkening with a BPC-157/TB-500 product). Long-term safety of injecting either is unknown.
Regulatory status and sport
Neither is an approved drug. GHK-Cu is an EU-listed cosmetic ingredient; injectable GHK-Cu was withdrawn from the FDA’s compounding nominations. BPC-157 was the subject of a July 2026 FDA advisory panel vote (8–6 for compounding for ulcerative colitis), with no FDA decision yet. WADA names BPC-157 under S0; GHK-Cu is not named, but S0 covers unapproved substances and WADA notes unnamed peptides may be prohibited.
Verdict
If your interest is skin, GHK-Cu is the one with (small) human data, in topical form. If it is tendon, joint or gut healing, BPC-157 is the one people use, but its human evidence is five small reports of very low certainty. For injected use of either, there is no controlled human evidence. Related: BPC-157 vs TB-500 · peptides for hair growth · peptides for skin tightening
Frequently asked questions
What is the difference between GHK-Cu and BPC-157?
Different peptides, different usesEvidence: Human data
GHK-Cu is a natural copper-binding tripeptide used mainly in skin care. BPC-157 is a synthetic 15-amino-acid peptide sold for tendon, joint and gut healing.
Is GHK-Cu or BPC-157 better for healing?
Unclear; human data are thinEvidence: Human data
For skin wounds, GHK-Cu has a small positive trial (diabetic foot ulcers, as a gel). For tendons and joints, only BPC-157 has been tried in people, in an uncontrolled 16-person review.
Can you take GHK-Cu and BPC-157 together?
Unknown; never testedEvidence: Limited
No study has tested the combination, by any route.
Is injectable GHK-Cu safe?
Not shown to be safeEvidence: Limited
It has never been tested in a human trial. The FDA warns of possible immune reactions from aggregation and impurities in injectable forms.
Are GHK-Cu and BPC-157 banned in sport?
BPC-157 yes; GHK-Cu may beEvidence: Law
BPC-157 is named under WADA S0. GHK-Cu is not named, but S0 covers unapproved substances and WADA notes unnamed peptides may be prohibited.
Sources
- Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper
- A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers
- Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin
- Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth
- The potential of GHK as an anti-aging peptide
- FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2 list; content current as of 22 Apr 2026)
- FDA Briefing Document, Pharmacy Compounding Advisory Committee, 23-24 July 2026: BPC-157-related bulk drug substances
- Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
- WADA 2027 Prohibited List: Summary of Major Modifications and Explanatory Notes
- World Anti-Doping Code International Standard: Prohibited List 2026